Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Brief: Effector Therapeutics Reports Positive Data Updates From Phase 2 Expansion Cohorts Evaluating Zotatifin In Patients With Er+ Metastatic Breast Cancer At The Asco 2023 Annual Meeting

eFFECTOR Therapeutics Inc  EFTR.O :
    * EFFECTOR THERAPEUTICS REPORTS POSITIVE DATA UPDATES FROM
PHASE 2
EXPANSION COHORTS EVALUATING ZOTATIFIN IN PATIENTS WITH ER+
METASTATIC BREAST CANCER AT THE ASCO 2023 ANNUAL MEETING
    * EFFECTOR THERAPEUTICS: PARTIAL RESPONSES IN 26% PATIENTS
TREATED
WITH ZOTATIFIN 0.07 MG/KG WITH FULVESTRANT & ABEMACICLIB IN
HEAVILY PRETREATED POPULATION
    * EFFECTOR THERAPEUTICS INC: BOTH COMBINATIONS WERE
GENERALLY WELL
TOLERATED WITH LARGE MAJORITY OF ADVERSE EVENTS GRADE 1 OR 2
    * EFFECTOR THERAPEUTICS INC: PARTIAL RESPONSE OBSERVED IN 1
OF 3
(33%) PATIENTS TREATED WITH ZOTATIFIN 0.1 MG/KG COMBINED WITH
FULVESTRANT (ZF DOUBLET)
    * EFFECTOR THERAPEUTICS INC: REPORTING DATA FROM COMPLETED
DOSE
ESCALATION IN SECOND HALF OF 2023

Source text for Eikon:  ID:nGNX9Mp7Nr 
Further company coverage:  EFTR.O

Recent news on Effector Therapeutics

See all news